Jason M. Broderick

Articles

Idecabtagene Vicleucel Highly Active in Heavily Pretreated Myeloma

May 30th 2020

Idecabtagene vicleucel induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline findings from the pivotal phase 2 KarMMA trial.

FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC

May 29th 2020

The FDA has approved atezolizumab plus bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Alpelisib Impresses in PIK3CA+ Breast Cancer After Progression on CDK Inhibition

May 29th 2020

Over half of patients with PIK3CA-positive, HR-positive/HER2-negative advanced breast cancer who had prior treatment with a CDK4/6 inhibitor plus an aromatase inhibitor were alive without disease progression 6 months after starting treatment with alpelisib plus fulvestrant.

Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma

May 29th 2020

Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.

Maintenance Niraparib Boosts PFS in Phase 3 Study of Chinese Patients With Ovarian Cancer

May 29th 2020

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.

NCCN Adds Rucaparib to Prostate Cancer Guidelines

May 28th 2020

The National Comprehensive Cancer Network has updated its Prostate Cancer guidelines to include the PARP inhibitor rucaparib.

FDA Grants Onvansertib Fast Track Designation in KRAS+ mCRC

May 28th 2020

The FDA has granted Fast Track designation to onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

FDA Waives ODAC Review of Margetuximab in HER2+ Breast Cancer

May 28th 2020

The FDA’s Oncologic Drugs Advisory Committee will no longer be meeting to review a Biologics License Application for margetuximab for the treatment of patients with HER2-positive breast cancer.

Atezolizumab Combo Approved in UK for Small Cell Lung Cancer

May 28th 2020

Atezolizumab in combination with carboplatin and etoposide has been approved in the UK for the frontline treatment of patients with extensive-stage small cell lung cancer.

FDA Approves Nivolumab/Ipilimumab Plus Chemo for Frontline NSCLC

May 27th 2020

The FDA has approved nivolumab combined with ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

Ipatasertib Survival Results Continue to Impress in TNBC

May 23rd 2020

Adding ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival in patients with triple-negative breast cancer.

Belumosudil Impresses in cGVHD, FDA Submission Started

May 21st 2020

Belumosudil (KD025) continued to show high levels of clinical activity in patients with previously treated chronic graft-versus-host disease.

Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma

May 20th 2020

A supplemental New Drug Application has been submitted to the FDA for the use of selinexor as a treatment for patients with multiple myeloma following at least 1 line of prior therapy.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved two companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with olaparib.

Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma

May 20th 2020

A supplemental New Drug Application has been submitted to the FDA for the use of selinexor as a treatment for patients with multiple myeloma following at least 1 line of prior therapy.

FDA Approves Olaparib for HRR-Mutant mCRPC

May 20th 2020

The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide or abiraterone acetate.

Immunotherapy-Based Triplet Highly Active in Frontline HER2+ Esophagogastric Cancer

May 19th 2020

Pembrolizumab combined with trastuzumab and chemotherapy demonstrated promising clinical activity in patients with HER2-positive metastatic esophagogastric cancer.

FDA Approves PD-L1 IHC 28-8 pharmDx as Companion Diagnostic for Nivolumab Plus Ipilimumab in NSCLC

May 18th 2020

The FDA has approved PD-L1 IHC 28-8 pharmDx for use as a companion diagnostic to identify patients with metastatic non–small cell lung cancer with PD-L1 tumor expression ≥1%, making them eligible for frontline treatment with nivolumab plus ipilimumab.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation for HER2+ NSCLC

May 18th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation for HER2+ NSCLC

May 18th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.